Non-nucleoside reverse transcriptase inhibitors - An overview

International Journal of STD and AIDS

Volumn 14, Issue 2, 2003, Pages 71-77

  Bell, C ^a   Matthews, G V ^a   Nelson, M R ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIHISTAMINIC AGENT; CAPAVIRINE; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STEROID; UNCLASSIFIED DRUG; ZIDOVUDINE;

CLINICAL TRIAL; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MENTAL DISEASE; NEUROTOXICITY; NIGHTMARE; PRIORITY JOURNAL; RASH; REVIEW; SOMNOLENCE; VERTICAL TRANSMISSION; VERTIGO;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037317499     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646203321156827     Document Type: Review

References (38)

1. Yeni P, Hammer S, Carpenter C, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;288:222-35
2. Albright A, Erickson-Viitanen S, Rayner MM, et al. Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro. AIDS Res Hum Retroviruses 2000;16:1527-37
3. Lafeuillaide A. Factors affecting adherence and convenience in antiretroviral therapy. Int J STD AIDS 2001;12(suppl 4):18-24
4. Lotthe A, Reynes J, Lo P, Mauboussin JM, Delm B. Sensio study: Assessment of late neuro psychiatric adverse reactions (NPAR) to efavirenz. MoPeB3250 Barcelona XIV International Aids Conference. July 2002.
5. Knobel H, Miro JM, Dominjo P, et al. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: The GESIDA 09/99 Study. J Acquir Immun Defic Syndr 2001;28:14-18
6. Den Brinker M, Wit FWNM, Wertheim-van Dillen PME, et al. Hepatitis B and C virus co-infection and the risk of hepatotoxicity of highly active antiretroviral therapy in HIV-1 infections. AIDS 2000;14:2895-902
7. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-8
8. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA 2002;288:199-206
9. Bartlett J. Severe liver toxicity in-patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. 8th Conference on Retroviruses and Opportunistic Infections Feb 2001 Abs 19
10. Morlese JS, Quazi NA, Gazzard BG, Nelson M. Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? AIDS, In Press
11. Wise M, Mistry K, Reid S. Neuropsychiatric complications of nevirapine treatment. BMJ 2002;324:879
12. Arribas J. Three year durability of response with efavirenz-containing regimen: 144 week follow-up from study 006. 11th Conference on Microbiology and Infectious Diseases. Turkey April 2001. Abs 366
13. Staszewski S, Morales-Ramirez J, Godofskye O. Longer time-to-treatment failure and durability of response with efavirenz+zidovudine+lamivudine: First analysis of full 1266 patient cohort from 006. Abstract 507, 39th ICAAC, Sept 26-29, San Francisco, 1999
14. Staszewski S, Morales-Ramirez J, Tashima T, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatments of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73
15. Nelson M, Staszewski S, Morales-Ramirez JO, et al. Successful virologic suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: posthoc results from Study 006. 10th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, May 28-31, 2000. Abstract 3-349
16. Tashima K, Staszewski S, Morales-Ramirez JO, et al. Continued viral suppression in patients treated with efavirenz (EFV)+zidovudine (ZDV)+lamivudine (3TC) at 112 weeks. 10th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, May 28-31, 2000. Abstract 3-401
17. Pulido F, Arribas JR, Miro JM, et al. Comparative study of efavirenz or protease inhibitor-based HAART in HIV infected antiretroviral naïve patients with <100 CD4 cell/ μL and opportunistic disease (EFA VIP-2 study). Barcelona IV International Aids Conference, July 2002 TuOrB1187/TuPeB4444
18. Cohen C, Elion R, Green S, et al. SUSTIVA (efavirenz) is highly effective and well tolerated in combination with the nucleosides stavudine and lamivudine (Study DMP 266-043) 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abs 538
19. Robbins G, Shafer R, Smeaton L. Antiretroviral strategies in naïve HIV+ subjects: comparison of sequential 3-drug regimens (ACTG 384) XIV International Aids Conference, Barcelona, July 2002 LbOr20A
20. Bartlett J, Johnson J, Herrera G, et al. Abacavir/lamivudine (ACV/3TC) in combination with efavirenz (NNRRI), amprenavir/ritonavir (PI) or stavudine (NNRTI): ESS400001 (CLASS) preliminary 96 week results. XIV International world AIDS Conference, Barcelona 2002 TuOrB1189
21. Squires K. The Atlantic study: A randomised open-label trial comparing two protease inhibitor sparing strategies versus a standard protease inhibitor containing regimen, final 48 week data. Programme and abstracts of the International AIDS Conference, July 9-14, 2000. LbPeB 7046
22. Podzamczer D, Ferrer E, Consiglio J, et al. A randomised multicenter trial comparing Combivir plus nelfinavir or nevirapine in HIV-1-infected naïve patients (the COMBINE study) 2001, 8th Conference on Retroviruses and Opportunistic Infections. Abs 327
23. Johnson M, Beall G, Badley A, et al. ABT-378/ritonavir (ABT-378/r) versus nelfinavir in antiretroviral naïve subjects: week 48 comparison in a phase III blinded randomised clinical trial. AIDS 2000;14(suppl 4): PL6.5 5
24. Montaner J, Reiss P, Cooper D, et al. A randomised, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-1 infected patients: The INCAS Trial. JAMA 1998;279:930-7
25. Pollard R. Factors predictive of durable HIV suppression in randomised double-blind trial with nevirapine, zidovudine and lamivudine in treatment-naïve patients with advanced AIDS. 7th Conference on Retroviruses and Opportunistic Infections. Abs 517 2000
26. Chiesi A, Mocroft A, Len G, et al. Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. AIDS 2002;13:2281-8
27. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: a cohort study. AIDS 2002;16:53-61
28. Keiser P, Nassar N, White C, Koen G, Moreno S. Cohort study shows treatment advantage across many risk factors for efavirenz vs nevirapine-containing regimens in treatment-naïve HIV-1 infected individuals. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Oct 2001, LB/P22
29. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virological and immunological response to regimens containing nevirapine or efavirenz with two nucleoside analogues in the Italian cohort naïve antiretroviral study (I.Co.N.A). J Infect Dis 2002;185:1062-9
30. Nunez M, Soriano V, Martin-Carbonero L, et al. SENC, Spanish efavirenz vs nevirapine comparison trial: A randomized, open-label study in HIV-infected naïve individuals. HIV Clin Trials 2002;3:186-94
31. Powderly N. The strategy of antiretroviral switch studies - a review. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000 Abs 1375
32. Martinez E, Podzamczer D, Ridera E, et al. Switching protease inhibitors of nevirapine, efavirenz or abacavir: A randomized, multicenter, open-label, simplification trial. 9th Conference on Retroviruses and Opportunistic Infections, 2002 Abs LB17
33. Maggiolo F, Migliorino M, Prawettoni G, et al. Management of protease inhibitor associated metabolic changes by substitutions with efavirenz in virologically controlled HIV-positive persons. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000 Abstract 1533
34. Patterson P, Zal C, Ochoa C, et al. A randomised study of treatment simplification with nevirapine or efavirenz in patients responding to a protease inhibitor based combination. XIV International AIDS Conference, Barcelona, July 2002 TuPeB4473
35. Delaugerre C, Wirden M, Simon A, et al. Resistance profile and cross-resistance to HIV-1 among 104 patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. 8th Conference on Retroviruses and Opportunistic Infections, February 2001, Abs 449
36. Grant RM, Kahn J, Warmerdam M. Transmission and transmissibility of drug resistant HIV-1. 9th Conference on Retroviruses and Opportunistic Infections, 2002
37. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802
38. Yeni P, Gazzard BG, Pozniak A. One-week therapy with TMC 125, a next generation NNRTI, demonstrates high potency in treatment-experienced HIV-1 infected individuals with phenotypic NNRTI-resistance. XIV International AIDS Conference, Barcelona July 2002 TuPeB4438